Evaluate the safety of human umbilical cord mesenchymal stem cells (hucMSCs) in POI treatment; Evaluate the effective hucMSCs in POI treatment. Compare different infusion mode, meanwhile compare with hormone replacement therapy (HRT) withdrawal, so that assessing the stem cell therapy.
Premature ovarian insufficiency (POI) or premature ovarian failure (POF), is the loss of function of the ovaries before age 40, which has the features of menstrual disorder with high gonadotropic hormone and low estrogen. The morbidity of POI is about 0.1% among woman before 40 years, 10-28% among woman with primary amenorrhea, and 4-18% among woman with secondary amenorrhea. Recent years research shows different sources of stem cell could be used to POI, and with effective results. Above all, this experiment designed to as a single center, random, and control experiment. treat POI patients wit human umbilical cord mesenchymal stem cells (MSCs). After regular follow-up and analysis, assessing the safety and effective of MSCs in POI treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
12
Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Menstrual changes
Observe the change of patients with irregular menstrual cycle
Time frame: 270 days
Kupperman score
Mild: \<14; moderate: 14-26; serious: \>26
Time frame: 270 days
hormone level
Test the level change of Follicle-Stimulating Hormone (FSH), estrogen (E2), and Anti Mullerian Hormone (AMH)
Time frame: 270 days
Follicular development
Observe the size of ovarian follicles in each cycle.
Time frame: 270 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.